Biolife Solutions Cmn (BLFS) 1.85 $BLFS BioLife
Post# of 273254
Posted On: 09/24/2016 11:20:09 PM
Biolife Solutions Cmn (BLFS) 1.85 $BLFS
BioLife Solutions' CryoStor® Embedded in Manufacturing Process for Promethera Biosciences HepaStem Cell-Based Treatment for Liver Disorders
PR Newswire - Thu Sep 15, 5:00AM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company"
, today announced that its clinical grade CryoStor freeze media has been embedded into the manufacturing process for HepaStem, a cell-based treatment developed by Promethera Biosciences, targeting several metabolic liver disorders such as hemophilia and large clinical indications including acute or chronic liver failure (ACLF), fibrosis and nonalcoholic steatohepatitis (NASH).
BLFS: 1.85 (+0.04)
BioLife Solutions' CryoStor® Integrated in Kolon Group's Cell-Mediated Gene Therapy for Osteoarthritis
PR Newswire - Wed Aug 24, 5:00AM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company" , today announced that its clinical grade CryoStor freeze media has been incorporated into the manufacturing process for Invossa, a cell-mediated gene therapy for knee osteoarthritis to be marketed by Kolon Life Science.
BLFS: 1.85 (+0.04)
BioLife Solutions Reports Results for Second Quarter 2016
PR Newswire - Thu Aug 11, 3:05PM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company" , today reported operational highlights and financial results for the three and six months ended June 30, 2016.
BLFS: 1.85 (+0.04)
BioLife Solutions Executes 10 Year Supply Agreement with Bellicum Pharmaceuticals for CryoStor® Use in Cellular Immunotherapies
PR Newswire - Wed Aug 10, 5:00AM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company" , today announced that it has entered into a ten year supply agreement with Bellicum Pharmaceuticals, a leading developer of cellular immunotherapies for cancers and orphan inherited blood disorders.
BLFS: 1.85 (+0.04)
BioLife Solutions to Report Second Quarter 2016 Financial Results and Provide Business Update on August 11, 2016
PR Newswire - Wed Aug 03, 5:00PM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company" , today announced that the Company's second quarter 2016 financial results will be released on Thursday, August 11, 2016, and that the Company will host a conference call and live webcast at 1:30 p.m. PT that afternoon. Management will provide an overview of the Company's financial results and a general business update.
BLFS: 1.85 (+0.04)
BioLife Solutions and MNX Global Logistics Partner to Support ImmunoCellular Therapeutics with Cold Chain Logistics in ICT-107 Phase 3 Clinical Trial in Glioblastoma
PR Newswire - Thu May 19, 5:00AM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company" , today announced that through its biologistex joint venture, it will partner with MNX Global Logistics to support the registrational phase 3 clinical trial being conducted by ImmunoCellular Therapeutics (NYSE MKT: IMUC) for their ICT-107 dendritic cell-based immunotherapy for newly diagnosed glioblastoma.
BLFS: 1.85 (+0.04), IMUC: 0.12 (unch)
BioLife Solutions Appoints Jim Mathers as New Vice President of Sales
PR Newswire - Wed May 18, 1:00PM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company" , today announced that it has appointed Jim Mathers to the position of Vice President of Sales, replacing Matt Snyder, who is retiring.
BLFS: 1.85 (+0.04)
BioLife Solutions Reports First Quarter 2016 Results
PR Newswire - Thu May 12, 3:05PM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company" , today reported financial results and operational highlights for the first quarter of 2016 and that it had entered into $4 million credit facility with its largest shareholder.
BLFS: 1.85 (+0.04)
BioLife Solutions to Report First Quarter 2016 Financial Results and Provide Business Update on May 12, 2016
PR Newswire - Fri May 06, 5:30AM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company" , today announced that the Company's first quarter 2016 financial results will be released on Thursday, May 12, 2016, and that the Company will host a conference call and live webcast at 1:30 p.m. PT that afternoon. Management will provide an overview of the Company's financial results and a general business update.
BLFS: 1.85 (+0.04)
BioLife Solutions Names Roderick de Greef Chief Financial Officer & Secretary
PR Newswire - Wed May 04, 5:00AM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers, today announced that Roderick de Greef has transitioned from Interim Chief Financial Officer and Secretary to full time employment and is relocating to the Seattle area.
BLFS: 1.85 (+0.04)
MNX Global Logistics and Biologistex, LLC Offer Proactive and Real-time Shipment Monitoring of Time and Temperature Sensitive Biologics, Vaccines & Cell Therapies
PR Newswire - Mon May 02, 7:00AM CDT
MNX Global Logistics, a global leader providing expedited and cold-chain transportation and logistics solutions to the life sciences and biopharmaceutical industry, announced today that it is expanding its GPS and cellular location-based real-time shipment integrity monitoring services through a partnership with Biologistex, LLC, a joint venture of BioLife Solutions (NASDAQ:BLFS) and SAVSU Technologies, a subsidiary of privately held Barson Corporation.
BLFS: 1.85 (+0.04)
Biologistex LLC and MNX Global Logistics Partner to Offer Enhanced Cold Chain Logistics Services for Time and Temperature Sensitive Biologics, Vaccines & Cell Therapies
PR Newswire - Tue Apr 26, 5:00AM CDT
Biologistex CCM, LLC, a joint venture of BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers, and SAVSU Technologies, LLC, a leading designer and manufacturer of innovative high performance passive storage and transport containers for temperature sensitive biologics and pharmaceuticals, today announced a partnership with MNX Global Logistics, a premier global provider of specialized, expedited transportation and logistics services, to offer enhanced cold chain logistics services to the biopharma, biobanking, and regenerative medicine markets via the biologistex SaaS app.
BLFS: 1.85 (+0.04)
BioLife Solutions Provides Update on Customer Cell Therapy Clinical Trials and Development Programs
PR Newswire - Mon Mar 14, 5:30AM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers, today provided an update on several customer clinical trials and development programs using cellular therapies and cellular immunotherapies in human regenerative medicine applications. Key developments include:
BLFS: 1.85 (+0.04)
BUYINS.NET: BLFS SqueezeTrigger Price is $1.94. There is $451,327 That Short Sellers Still Need To Cover.
M2 - Mon Feb 01, 4:22AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring Biolife Solutions Inc (NASDAQ:BLFS) in real time and just received an alert that BLFS is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 229100 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $1.94. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
BLFS: 1.85 (+0.04)
BioLife Solutions to Present at 18th Annual BIO CEO & Investors Conference
PR Newswire - Wed Jan 27, 5:00AM CST
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers, announced today that the Company will be presenting at the 18th Annual BIO CEO & Investor Conference being held February 8-9, 2016 at the Waldorf Astoria in New York City. Mike Rice, Chief Executive Officer at BioLife Solutions, will be presenting at 5:00 PM ET on Monday, February 8th in the Park South room during the conference's Tools/Drug Development Support Technology Track.
BLFS: 1.85 (+0.04)
BUYINS.NET: BLFS SqueezeTrigger Price is $1.94. There is $455,909 That Short Sellers Still Need To Cover.
M2 - Mon Jan 25, 6:43AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring Biolife Solutions Inc (NASDAQ:BLFS) in real time and just received an alert that BLFS is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 229100 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $1.94. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
BLFS: 1.85 (+0.04)
New Journal Articles Cite Expanded Use of BioLife Solutions Products in Clinical Cell Therapy Applications
PR Newswire - Mon Jan 25, 5:00AM CST
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers today announced that two recently published journal articles cite expanded use of the Company's CryoStor cell freeze media in pre-clinical safety studies and clinical trials of cellular therapies for liver transplantation and heart failure.
BLFS: 1.85 (+0.04)
BioLife Solutions Announces 2015 Biopreservation Media Revenue Growth of 30%
PR Newswire - Thu Jan 07, 5:00AM CST
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers today announced preliminary full year 2015 revenue of $6.4 million, including a 30% increase in core biopreservation media revenue over the prior year.
BLFS: 1.85 (+0.04)
BioLife Solutions Distributor STEMCELL Technologies Will Test the evo(TM) Smart Shipper and Cloud Based biologistex(TM) Cold Chain Management App
PR Newswire - Wed Jan 06, 5:00AM CST
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company" , today announced that privately held, Vancouver, BC-based STEMCELL Technologies will test BioLife's evo Smart Shipper and biologistex cold chain SaaS on a variety of temperature sensitive products for research in areas such as cellular therapies, blood cancers, and solid tumors.
BLFS: 1.85 (+0.04)
BioLife Solutions Customer Capricor Therapeutics Provides Update on Heart Failure Cell Therapy Safety Data at American Heart Association Scientific Sessions
PR Newswire - Mon Nov 23, 5:00AM CST
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company" , today announced its customer Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, announced positive six-month safety and adverse event data from its ongoing DYNAMIC (Dilated cardiomYopathy iNtervention with Allogeneic MyocardIally-regenerative Cells) clinical trial evaluating CAP-1002 in patients with advanced heart failure. The data were highlighted in a poster presentation on November 9 at the 2015 American Heart Association (AHA) Scientific Sessions in Orlando, FL.
CAPR: 3.51 (-0.12), BLFS: 1.85 (+0.04)
BioLife Solutions' CryoStor® Embedded in Manufacturing Process for Promethera Biosciences HepaStem Cell-Based Treatment for Liver Disorders
PR Newswire - Thu Sep 15, 5:00AM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company"
, today announced that its clinical grade CryoStor freeze media has been embedded into the manufacturing process for HepaStem, a cell-based treatment developed by Promethera Biosciences, targeting several metabolic liver disorders such as hemophilia and large clinical indications including acute or chronic liver failure (ACLF), fibrosis and nonalcoholic steatohepatitis (NASH). BLFS: 1.85 (+0.04)
BioLife Solutions' CryoStor® Integrated in Kolon Group's Cell-Mediated Gene Therapy for Osteoarthritis
PR Newswire - Wed Aug 24, 5:00AM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company"
, today announced that its clinical grade CryoStor freeze media has been incorporated into the manufacturing process for Invossa, a cell-mediated gene therapy for knee osteoarthritis to be marketed by Kolon Life Science. BLFS: 1.85 (+0.04)
BioLife Solutions Reports Results for Second Quarter 2016
PR Newswire - Thu Aug 11, 3:05PM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company"
, today reported operational highlights and financial results for the three and six months ended June 30, 2016. BLFS: 1.85 (+0.04)
BioLife Solutions Executes 10 Year Supply Agreement with Bellicum Pharmaceuticals for CryoStor® Use in Cellular Immunotherapies
PR Newswire - Wed Aug 10, 5:00AM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company"
, today announced that it has entered into a ten year supply agreement with Bellicum Pharmaceuticals, a leading developer of cellular immunotherapies for cancers and orphan inherited blood disorders. BLFS: 1.85 (+0.04)
BioLife Solutions to Report Second Quarter 2016 Financial Results and Provide Business Update on August 11, 2016
PR Newswire - Wed Aug 03, 5:00PM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company"
, today announced that the Company's second quarter 2016 financial results will be released on Thursday, August 11, 2016, and that the Company will host a conference call and live webcast at 1:30 p.m. PT that afternoon. Management will provide an overview of the Company's financial results and a general business update. BLFS: 1.85 (+0.04)
BioLife Solutions and MNX Global Logistics Partner to Support ImmunoCellular Therapeutics with Cold Chain Logistics in ICT-107 Phase 3 Clinical Trial in Glioblastoma
PR Newswire - Thu May 19, 5:00AM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company"
, today announced that through its biologistex joint venture, it will partner with MNX Global Logistics to support the registrational phase 3 clinical trial being conducted by ImmunoCellular Therapeutics (NYSE MKT: IMUC) for their ICT-107 dendritic cell-based immunotherapy for newly diagnosed glioblastoma. BLFS: 1.85 (+0.04), IMUC: 0.12 (unch)
BioLife Solutions Appoints Jim Mathers as New Vice President of Sales
PR Newswire - Wed May 18, 1:00PM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company"
, today announced that it has appointed Jim Mathers to the position of Vice President of Sales, replacing Matt Snyder, who is retiring. BLFS: 1.85 (+0.04)
BioLife Solutions Reports First Quarter 2016 Results
PR Newswire - Thu May 12, 3:05PM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company"
, today reported financial results and operational highlights for the first quarter of 2016 and that it had entered into $4 million credit facility with its largest shareholder. BLFS: 1.85 (+0.04)
BioLife Solutions to Report First Quarter 2016 Financial Results and Provide Business Update on May 12, 2016
PR Newswire - Fri May 06, 5:30AM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company"
, today announced that the Company's first quarter 2016 financial results will be released on Thursday, May 12, 2016, and that the Company will host a conference call and live webcast at 1:30 p.m. PT that afternoon. Management will provide an overview of the Company's financial results and a general business update. BLFS: 1.85 (+0.04)
BioLife Solutions Names Roderick de Greef Chief Financial Officer & Secretary
PR Newswire - Wed May 04, 5:00AM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers, today announced that Roderick de Greef has transitioned from Interim Chief Financial Officer and Secretary to full time employment and is relocating to the Seattle area.
BLFS: 1.85 (+0.04)
MNX Global Logistics and Biologistex, LLC Offer Proactive and Real-time Shipment Monitoring of Time and Temperature Sensitive Biologics, Vaccines & Cell Therapies
PR Newswire - Mon May 02, 7:00AM CDT
MNX Global Logistics, a global leader providing expedited and cold-chain transportation and logistics solutions to the life sciences and biopharmaceutical industry, announced today that it is expanding its GPS and cellular location-based real-time shipment integrity monitoring services through a partnership with Biologistex, LLC, a joint venture of BioLife Solutions (NASDAQ:BLFS) and SAVSU Technologies, a subsidiary of privately held Barson Corporation.
BLFS: 1.85 (+0.04)
Biologistex LLC and MNX Global Logistics Partner to Offer Enhanced Cold Chain Logistics Services for Time and Temperature Sensitive Biologics, Vaccines & Cell Therapies
PR Newswire - Tue Apr 26, 5:00AM CDT
Biologistex CCM, LLC, a joint venture of BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers, and SAVSU Technologies, LLC, a leading designer and manufacturer of innovative high performance passive storage and transport containers for temperature sensitive biologics and pharmaceuticals, today announced a partnership with MNX Global Logistics, a premier global provider of specialized, expedited transportation and logistics services, to offer enhanced cold chain logistics services to the biopharma, biobanking, and regenerative medicine markets via the biologistex SaaS app.
BLFS: 1.85 (+0.04)
BioLife Solutions Provides Update on Customer Cell Therapy Clinical Trials and Development Programs
PR Newswire - Mon Mar 14, 5:30AM CDT
BioLife Solutions, Inc. (NASDAQ: BLFS), a developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers, today provided an update on several customer clinical trials and development programs using cellular therapies and cellular immunotherapies in human regenerative medicine applications. Key developments include:
BLFS: 1.85 (+0.04)
BUYINS.NET: BLFS SqueezeTrigger Price is $1.94. There is $451,327 That Short Sellers Still Need To Cover.
M2 - Mon Feb 01, 4:22AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring Biolife Solutions Inc (NASDAQ:BLFS) in real time and just received an alert that BLFS is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 229100 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $1.94. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
BLFS: 1.85 (+0.04)
BioLife Solutions to Present at 18th Annual BIO CEO & Investors Conference
PR Newswire - Wed Jan 27, 5:00AM CST
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers, announced today that the Company will be presenting at the 18th Annual BIO CEO & Investor Conference being held February 8-9, 2016 at the Waldorf Astoria in New York City. Mike Rice, Chief Executive Officer at BioLife Solutions, will be presenting at 5:00 PM ET on Monday, February 8th in the Park South room during the conference's Tools/Drug Development Support Technology Track.
BLFS: 1.85 (+0.04)
BUYINS.NET: BLFS SqueezeTrigger Price is $1.94. There is $455,909 That Short Sellers Still Need To Cover.
M2 - Mon Jan 25, 6:43AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring Biolife Solutions Inc (NASDAQ:BLFS) in real time and just received an alert that BLFS is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 229100 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $1.94. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
BLFS: 1.85 (+0.04)
New Journal Articles Cite Expanded Use of BioLife Solutions Products in Clinical Cell Therapy Applications
PR Newswire - Mon Jan 25, 5:00AM CST
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers today announced that two recently published journal articles cite expanded use of the Company's CryoStor cell freeze media in pre-clinical safety studies and clinical trials of cellular therapies for liver transplantation and heart failure.
BLFS: 1.85 (+0.04)
BioLife Solutions Announces 2015 Biopreservation Media Revenue Growth of 30%
PR Newswire - Thu Jan 07, 5:00AM CST
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers today announced preliminary full year 2015 revenue of $6.4 million, including a 30% increase in core biopreservation media revenue over the prior year.
BLFS: 1.85 (+0.04)
BioLife Solutions Distributor STEMCELL Technologies Will Test the evo(TM) Smart Shipper and Cloud Based biologistex(TM) Cold Chain Management App
PR Newswire - Wed Jan 06, 5:00AM CST
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company"
, today announced that privately held, Vancouver, BC-based STEMCELL Technologies will test BioLife's evo Smart Shipper and biologistex cold chain SaaS on a variety of temperature sensitive products for research in areas such as cellular therapies, blood cancers, and solid tumors. BLFS: 1.85 (+0.04)
BioLife Solutions Customer Capricor Therapeutics Provides Update on Heart Failure Cell Therapy Safety Data at American Heart Association Scientific Sessions
PR Newswire - Mon Nov 23, 5:00AM CST
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company"
, today announced its customer Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, announced positive six-month safety and adverse event data from its ongoing DYNAMIC (Dilated cardiomYopathy iNtervention with Allogeneic MyocardIally-regenerative Cells) clinical trial evaluating CAP-1002 in patients with advanced heart failure. The data were highlighted in a poster presentation on November 9 at the 2015 American Heart Association (AHA) Scientific Sessions in Orlando, FL. CAPR: 3.51 (-0.12), BLFS: 1.85 (+0.04)
(0)
(0)Scroll down for more posts ▼